If you take diuretics, have heart failure, liver disease, or adrenal insufficiency, serum sodium testing is non-negotiable—abnormalities can develop silently and escalate rapidly. Even if you have none of these conditions, sodium is a window into fluid regulation and hormonal signalling, especially if you experience unexplained fatigue, nausea, headaches, or confusion that might hint at electrolyte disturbance.

Serum sodium matters because it is tightly regulated by your kidneys and hormones (antidiuretic hormone, or ADH; the renin-angiotensin-aldosterone system, or RAAS). Any drift outside 135–145 mmol/L reflects dysfunction in these regulatory axes—not dietary habit. This distinction is critical: if you read that “salt raises blood pressure”, that is a separate conversation about sodium intake and blood pressure regulation. Your serum sodium level is about water balance and systemic disease, not dietary sodium consumption.

For longevity, an annual baseline serum sodium paired with potassium, creatinine, and urea establishes your electrolyte baseline and flags early renal or endocrine dysfunction before symptoms emerge.

• Flags water-balance dysfunction. Serum sodium directly reflects whether your kidneys are retaining or losing water appropriately. Abnormal sodium reveals disorders of ADH secretion, renal water handling, or both that would otherwise remain invisible.

• Identifies SIADH and hyponatraemia risk. Syndrome of inappropriate antidiuretic hormone (SIADH) causes persistent hyponatraemia and is common in malignancy, CNS disease, and pulmonary infection. Diuretic use, heart failure, and liver failure also cause hyponatraemia; sodium testing catches these patterns early.

• Detects dehydration and hypernatraemia. Elevated serum sodium (hypernatraemia) indicates net water loss relative to sodium and signals dehydration, diabetes insipidus, or inadequate fluid intake. This is clinically urgent.

• Contextualizes other renal markers. Serum sodium paired with potassium, creatinine, and urea reveals the full electrolyte and renal function picture. A person with normal creatinine but abnormal sodium may have early renal disease affecting specific electrolyte transport.

• Guides medication safety. If you take ACE inhibitors, thiazide diuretics, loop diuretics, NSAIDs, or SSRIs—all of which can affect sodium handling—baseline and periodic sodium monitoring ensures these drugs are not causing electrolyte disturbance.

Sodium as an electrolyte and osmotic regulator. Sodium is the dominant positive ion (cation) in extracellular fluid and the key osmotic particle that holds water outside cells. Your kidneys filter sodium continuously, then reabsorb it selectively to maintain plasma osmolality—the concentration of dissolved particles—within a narrow range (280–295 mOsm/kg). When osmolality rises (too much sodium relative to water), the pituitary releases ADH (also called vasopressin), which makes the kidneys retain water, diluting the blood back to normal. When osmolality falls (too much water relative to sodium), ADH is suppressed, and the kidneys excrete dilute urine. This exquisite feedback loop keeps serum sodium pinned between 135 and 145 mmol/L.

Why sodium drifts in disease. Hyponatraemia (sodium <135 mmol/L) means the kidneys are retaining too much water relative to sodium. This happens in SIADH (where a tumour or brain lesion causes the pituitary to secrete ADH inappropriately), in heart failure (where low cardiac output triggers RAAS activation and ADH release to preserve blood volume), in liver failure (where portal hypertension and hepatic decompensation impair sodium handling), in adrenal insufficiency (where lack of aldosterone causes renal sodium wasting), and with diuretic use (where loop and thiazide diuretics block tubular sodium reabsorption). Hypernatraemia (sodium >145 mmol/L) means net water loss—either from inadequate intake (in elderly or cognitively impaired patients), from excessive losses (diabetes insipidus, where the kidneys cannot respond to ADH), or from dehydration with insensible losses exceeding intake. Primary polydipsia—compulsive drinking—can paradoxically cause both hyponatraemia (from ADH suppression failing to match fluid intake) and later hypernatraemia if dehydration supervenes.

Mortality and severity. Both hypo- and hypernatraemia carry mortality risk. Hyponatraemia is surprisingly common (present in “only” 15–30% of hospitalised patients in some cohorts) and is independently associated with increased in-hospital and long-term mortality, even after adjustment for severity of underlying disease. Severe hyponatraemia (<125 mmol/L) can cause seizures, coma, and death from cerebral oedema. Hypernatraemia is less common but equally sinister—it signals significant dehydration or CNS disease and carries high mortality, particularly in elderly patients.

• Early detection of hidden disease. Hyponatraemia often appears before other signs of heart failure, liver disease, or malignancy become apparent. An abnormal serum sodium in an asymptomatic person should trigger investigation for occult disease, not be dismissed as “just low”.

• Independent mortality predictor. In observational cohorts and RCT subgroups, abnormal serum sodium predicts mortality independent of the underlying disease causing it. This means sodium is both a marker of serious illness and possibly a direct contributor to poor outcomes through effects on cellular and neurological function.

• Medication safety signal. Diuretics, ACE inhibitors, thiazides, NSAIDs, and SSRIs all perturb sodium handling. Regular sodium monitoring in people taking these agents catches drug-induced electrolyte disturbance before symptomatic hyponatraemia develops—a common cause of hospitalisation in elderly patients.

• Synergy with renal markers. Serum sodium contextualized with creatinine, urea, and potassium reveals whether renal dysfunction is glomerular (affecting all electrolytes) or tubular (affecting sodium and potassium preferentially). This distinction guides further diagnostic workup.

• Standard Swedish clinical reference (135–145 mmol/L): This is the widely accepted normal range for serum sodium across European and US guidelines. Values outside this range are flagged as abnormal and warrant investigation.

• Loovi optimal (longevity baseline): 138–142 mmol/L. This is a narrower “optimal” range reflecting the physiological set point. Most healthy people cluster toward the midpoint (138–140 mmol/L). Persistent sodium near the edges of the normal range (135–137 or 143–145 mmol/L) may signal subclinical disease or medication effects worth investigating further.

The distinction between “normal” and “optimal” reflects the fact that serum sodium is so tightly regulated that values at the extremes of the normal range can hint at underlying dysfunction. A person with sodium persistently at 135 mmol/L is not clinically hyponatraemic by definition, but this value is unusual in healthy people and may reflect early ADH dysregulation, mild renal disease, or medication effect. Similarly, sodium at 145 mmol/L suggests a tendency toward dehydration or diabetes insipidus. Serial monitoring within the normal range can catch drift before clinical abnormality emerges.

Low (sodium <135 mmol/L; hyponatraemia). This indicates your kidneys are retaining water relative to sodium—ADH is too high or renal water handling is impaired. The cause determines urgency: mild hyponatraemia (130–135 mmol/L) develops slowly in heart failure, liver disease, or SIADH and may present only with fatigue or mild nausea. Moderate hyponatraemia (125–130 mmol/L) causes headache, confusion, and nausea and warrants investigation and treatment. Severe hyponatraemia (<125 mmol/L) is a medical emergency—it causes seizures, cerebral oedema, and death and demands urgent hospitalisation. All hyponatraemia requires paired assessment of osmolality, urine osmolality, and ADH to determine mechanism.

Optimal (138–142 mmol/L). This range is the physiological sweet spot where your kidneys are balancing sodium and water normally. Most healthy people sit here. Paired with normal potassium and creatinine, this is reassuring for renal and endocrine health.

High (sodium >145 mmol/L; hypernatraemia). This indicates net water loss—either from inadequate intake, excessive losses (sweating, diarrhoea, polyuria), or inability to conserve water (diabetes insipidus). Hypernatraemia is less common than hyponatraemia but carries high mortality, particularly in elderly or hospitalized patients. Mild hypernatraemia (145–150 mmol/L) causes thirst and polyuria. Moderate hypernatraemia (150–160 mmol/L) causes confusion, lethargy, and risk of seizure. Severe hypernatraemia (>160 mmol/L) is life-threatening. All hypernatraemia requires assessment of fluid intake, urine output, and ADH responsiveness to diagnose the cause.

Persistent values at range edges (135–137 or 143–145 mmol/L). These are within the normal range but unusual. Persistent sodium at the low edge may hint at subclinical SIADH, medication effect (SSRIs, carbamazepine, oxcarbazepine), or early renal or adrenal disease. Persistent sodium at the high edge may signal chronic dehydration, early diabetes insipidus, or occult water loss. Serial monitoring and paired assessment of other electrolytes can clarify whether this reflects stable individual variation or emerging disease.

Factors that influence sodium. Acute dehydration (from diarrhoea, vomiting, excessive sweating, or poor fluid intake) raises sodium transiently; rehydration normalizes it within hours. Acute overhydration (from excessive drinking or IV fluid administration) lowers sodium acutely; fluid restriction normalizes it over hours to days. SSRIs, carbamazepine, oxcarbazepine, and other drugs that enhance ADH secretion lower sodium chronically. Thiazide and loop diuretics lower sodium by causing renal wasting. NSAIDs impair renal water excretion and can cause hyponatraemia. Adrenal insufficiency, hypothyroidism, and heart failure sustain hyponatraemia. Recent surgery or head trauma can trigger transient SIADH. Pregnancy physiologically lowers the osmolality set point, lowering serum sodium by ~5 mmol/L; this is normal and reverses postpartum.

• Syndrome of inappropriate antidiuretic hormone (SIADH). The pituitary secretes ADH despite low serum osmolality, causing the kidneys to retain water and dilute the blood. SIADH is caused by small-cell lung cancer, CNS disease (head injury, subarachnoid haemorrhage, meningitis), pulmonary infection, and certain medications (SSRIs, carbamazepine, cyclophosphamide). It is the most common cause of hyponatraemia in hospitalised patients.

• Heart failure, liver failure, and adrenal insufficiency. In heart failure, low cardiac output triggers RAAS activation and ADH release as the body attempts to preserve blood volume; this causes hyponatraemia despite volume overload. In cirrhosis, portal hypertension and hepatic dysfunction impair renal water excretion and sodium handling. In adrenal insufficiency, lack of aldosterone causes renal sodium wasting. All three are common causes of symptomatic hyponatraemia.

• Diuretic use. Thiazide diuretics cause hyponatraemia by blocking distal tubular sodium reabsorption and impairing the kidney's ability to excrete dilute urine. Loop diuretics cause less hyponatraemia than thiazides but still carry risk. This is a medication-induced cause and is reversible.

• Diabetes insipidus and dehydration. Diabetes insipidus (central or nephrogenic) prevents the kidneys from responding to ADH, causing polyuria and hypernatraemia if fluid intake cannot keep pace. Insensible losses (sweating, respiration) without adequate fluid replacement cause hypernatraemia. In elderly or cognitively impaired patients, inadequate fluid intake drives hypernatraemia.

• Primary polydipsia. Compulsive drinking (psychiatric condition) can cause hyponatraemia acutely from ADH suppression failing to match fluid intake. Later, if drinking ceases abruptly, hypernatraemia can develop from rebound dehydration.

Fluid and electrolyte balance. If you have normal kidneys and no endocrine disease, your sodium regulates itself through thirst and ADH feedback. Drink when thirsty; do not force excessive fluid intake in an attempt to “dilute” sodium, as this can paradoxically lower sodium further in some disease states. If you have heart failure, liver disease, or SIADH, fluid restriction (often to 1000–1500 mL/day) is a key therapeutic lever; your clinician will advise specific targets based on your disease and severity.

Medication review. If you take SSRIs, thiazide diuretics, NSAIDs, or other drugs that perturb sodium handling, periodic monitoring (annual or more frequent if symptoms emerge) catches drug-induced hyponatraemia before it becomes symptomatic. If hyponatraemia develops, switching drugs or adjusting doses may restore normal sodium—a conversation with your clinician.

Disease-specific interventions. If hyponatraemia is caused by SIADH, treatment depends on the underlying cause: treating lung cancer, stopping offending medications, managing CNS disease, or addressing infection. Vaptans (V2-receptor antagonists like tolvaptan) can raise sodium in SIADH by blocking ADH's water-reabsorption effect; these are specialist therapies. In heart failure, ACE inhibitors and beta-blockers improve cardiac function and often improve hyponatraemia secondarily. In adrenal insufficiency, glucocorticoid and mineralocorticoid replacement restores sodium. In diabetes insipidus, desmopressin (ADH analogue) or nephrogenic treatments (thiazides, NSAIDs, amiloride) address the underlying defect.

Acute hyponatraemia management. If hyponatraemia develops acutely (over hours), it is more symptomatic and dangerous than chronic hyponatraemia because the brain does not have time to compensate osmotically. Acute symptomatic hyponatraemia (<125 mmol/L with seizures or altered consciousness) is treated with hypertonic saline; this is an emergency requiring hospital care. Chronic hyponatraemia is corrected more slowly (typically <8–10 mmol/L per 24 hours) to avoid osmotic demyelination syndrome, a rare but serious complication of over-rapid correction.

Individual variation and Swedish context. Sweden's recent observational and Mendelian randomization data on sodium intake and mortality show a U-shaped relationship—both very low and very high dietary sodium are associated with excess mortality. However, this is about dietary sodium consumption and blood pressure regulation, not serum sodium. Your serum sodium level reflects water balance and disease state, not dietary habits. The right approach to serum sodium depends on the underlying disease causing the abnormality, which is what a Loovi longevity doctor investigates in consultation.

Serum sodium without context is a red flag without a story. A person with sodium at 133 mmol/L could have SIADH, heart failure, liver disease, medication effect, or adrenal insufficiency—five very different diagnoses requiring five different treatments. To distinguish between them, you need paired markers: potassium (to assess aldosterone-axis function), creatinine and urea (to assess renal function), osmolality (to determine if hyponatraemia is hypo-osmolar, iso-osmolar, or hyperosmolar), urine osmolality and urine sodium (to assess the kidney's response to abnormal serum osmolality), and TSH and cortisol (to screen for thyroid and adrenal disease).

The Loovi Membership measures 120+ biomarkers annually, including the full electrolyte panel (sodium, potassium, chloride), renal function (creatinine, urea, eGFR), and endocrine screening (TSH, cortisol, aldosterone). Paired with unrushed 1-on-1 longevity doctor consultations, physical performance tests (strength, mobility, VO2 max), and an evolving personalized health plan, Loovi hands off the hard work of interpretation and investigation to clinical experts. From 295 SEK/month, Friskvårdsbidrag-approved, with drop-in testing at 80+ Swedish clinics and results in 3 days.